Hydroxychloroquine Administration for Reduction of Pexophagy
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 3
- 试验地点
- 1
- 主要终点
- Change in the red blood cell levels of plasmalogen.
研究概览
简要总结
A series of N-of-1, crossover, randomized, placebo-controlled, double-blinded trial. Hydroxychloroquine (HCQ) and a crossover to placebo (order is randomized and blinded) will be administered in liquid suspension for 84 days (12 weeks) each with an 84 day washout in between. We hypothesize that HCQ will reduce peroxisomal turnover, which will arrest ongoing injury in PBDs caused by PEX1, PEX6 or PEX26.
详细描述
HARP is a phase II/III, double-blind, placebo-controlled, randomized, crossover series N-of-1 study of the effect of hydroxychloroquine (HCQ) in patients with peroxisomal biogenesis disorders (PBD-ZSD). Patients eligible for the study must have a laboratory diagnosis of PEX1, PEX6 or PEX26 dependent PBD-ZSD from a CLIA or SCC-certified clinical laboratory, a history of abnormal VLCFA levels, and must be at least 84 days from their last HCQ dose. Patients will be excluded for known sensitivity to HCQ, known glucose-6-phosphate dehydrogenase deficiency, if they have an expected survival of less than 9 months or if they are participating in another interventional clinical trial.
HCQ will be administered at a dose of 4mg/kg/day divided into two doses, as a liquid suspension that can be given orally or through nasogastric or gastric tube. Within the study, HCQ or placebo will be given for 84 days, followed by a washout period of 84 days followed by an 84 day crossover to the alternative therapy to assess the effect the study measures.
Study measures will be completed at four intervals (initiation, end of period 1, start of period 2, end of trial). Ophthalmological monitoring of patients has three components, electroretinogram (ERG), visual acuity testing and optical coherence tomography (OCT). Plasma levels of very long-chain fatty acids (VLCFA), plasmalogen and phytanic acid will be assessed. Parents will also be administered The Pediatric Inventory for Parents (PIP), a questionnaire that was developed to evaluate the stress associated with parenting a seriously ill child, at the end of period 1 and period 2.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
All parties will be masked except for research pharmacy who will do the randomization.
入排标准
- 年龄范围
- 6 Months 至 40 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed with a peroxisomal defect due to PEX1, PEX6 or PEX26 through a SCC or CLIA-certified clinical genetic testing laboratory.
- •Abnormal plasma very-long-chain fatty acid levels.
- •All therapies available in Canada have been considered and ruled out, have failed or were justified as being unsuitable for the patient. We note that there are no therapies available.
- •At least 84 days from last HCQ dose
排除标准
- •Known sensitivity to HCQ.
- •Known Glucose-6-phosphate dehydrogenase deficiency.
- •Expected survival is less than six months.
- •The patient does not provide informed consent.
- •The patient is participating in another interventional clinical trial.
研究组 & 干预措施
Hydroxychloroquine
Hydroxychloroquine: liquid suspension, 4mg/kg/day by mouth, divided bid for 84 days.
干预措施: Hydroxychloroquine (Drug)
Placebo
Liquid suspension compounded to mimic the taste, appearance and texture of the investigational agent.
干预措施: Placebo (Drug)
结局指标
主要结局
Change in the red blood cell levels of plasmalogen.
时间窗: 12 week. Measurements at Day 0, Day 84(+/-7 days) of each treatment arm.
Change in the red blood cell levels of plasmalogen (18:0 dimethylacetals/18:0 ratio).
Change in the plasma levels of phytanic acid.
时间窗: 12 week. Measurements at Day 0, Day 84(+/-7 days) of each treatment arm.
Change in the plasma levels of phytanic acid.
Change in the plasma levels of very-long chain fatty acids.
时间窗: 12 week. Measurements at Day 0, Day 84(+/-7 days) of each treatment arm.
Change in the plasma levels of very-long chain fatty acids (C26/C22).
Electroretinogram (ERG) voltage changes.
时间窗: 12 week. Measurements at Day 0, Day 84(+/-7 days) of each treatment arm.
Electroretinograms are a diagnostic test that measures the electric activity within cells in response to stimulus. ERG voltages are depressed in peroxisomal disease, and the quantitative evaluation of ERG voltage is another measure that has been used as an endpoint for clinical trials in peroxisomal disease. Change in b-wave voltage before and after treatment period.
次要结局
- Eye examination: Optical Coherence Tomography(12 week. Measurements at Day 0, Day 84(+/-7 days) of each treatment arm.)
- Pediatric Inventory for Parents (PIP) following the treatment arms.(36 week. Measurements following each treatment arm.)
- Eye examination: Visual Acuity(12 week. Measurements at Day 0, Day 84(+/-7 days) of each treatment arm.)
研究者
Neal Sondheimer
Staff Physician - Clinical and Metabolic Genetics
The Hospital for Sick Children